# EDGAR Filing Document

**Accession Number:** 0001933414
**File Stem:** 0001628280-23-005044
**Filing Date:** 2023-2
**Character Count:** 29416
**Document Hash:** 3ba6526cddfa5eb3e81a3b5afc901e67
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-005044.hdr.sgml**: 20230224

**ACCESSION NUMBER**: 0001628280-23-005044

**CONFORMED SUBMISSION TYPE**: SC 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230224

**DATE AS OF CHANGE**: 20230224

**GROUP MEMBERS**: SAMSARA BIOCAPITAL GP, LLC

**GROUP MEMBERS**: SRINIVAS AKKARAJU

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mineralys Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001933414
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94000
- **FILM NUMBER:** 23666859

**BUSINESS ADDRESS:**
- **STREET 1:** 150 N. RADNOR CHESTER ROAD
- **STREET 2:** SUITE F200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** (888) 378-6240

**MAIL ADDRESS:**
- **STREET 1:** 150 N. RADNOR CHESTER ROAD
- **STREET 2:** SUITE F200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Samsara BioCapital, L.P.
- **CENTRAL INDEX KEY:** 0001699737
- **IRS NUMBER:** 813958301
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 628 MIDDLEFIELD ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
- **BUSINESS PHONE:** (650) 285-4270

**MAIL ADDRESS:**
- **STREET 1:** 628 MIDDLEFIELD ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13D**

**Under the Securities Exchange Act of 1934**

**(Amendment No.)**

**Mineralys Therapeutics, Inc.**

(Name of Issuer)

**<u>Common Stock</u>**

(Title of Class of Securities)

**<u>603170101</u>**

(CUSIP Number)

**Abrar Hussain**

**Samsara BioCapital**

**628 Middlefield Road**

**Palo Alto, CA 94301**

**650-285-4270**

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

**February 14, 2023**

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [ ]

*Note*: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

_____________

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes

------

---

| | | |
|:---|:---|:---|
| CUSIP No. 20451W101 | **13D** | Page 1 of 8 pages |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **1** | Names of Reporting Persons<br>**Samsara BioCapital, L.P.** | Names of Reporting Persons<br>**Samsara BioCapital, L.P.** | Names of Reporting Persons<br>**Samsara BioCapital, L.P.** | Names of Reporting Persons<br>**Samsara BioCapital, L.P.** |
| **2** | Check the Appropriate Box if a Member of a Group | Check the Appropriate Box if a Member of a Group | Check the Appropriate Box if a Member of a Group | (a) [ ](b) [ ] |
| **3** | SEC Use Only | SEC Use Only | SEC Use Only | SEC Use Only |
| **4** | Source of Funds (See Instructions)<br>**OO** | Source of Funds (See Instructions)<br>**OO** | Source of Funds (See Instructions)<br>**OO** | Source of Funds (See Instructions)<br>**OO** |
| **5** | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ] |
| **6** | Citizenship or Place of Organization<br>**Delaware** | Citizenship or Place of Organization<br>**Delaware** | Citizenship or Place of Organization<br>**Delaware** | Citizenship or Place of Organization<br>**Delaware** |
| **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **7** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>**0** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>**0** |
| **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **8** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power<br>**4,519,361** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power<br>**4,519,361** |
| **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **9** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power<br>**0** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power<br>**0** |
| **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **10** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power<br>**4,519,361** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power<br>**4,519,361** |
| **11** | Aggregate Amount Beneficially Owned by Each Reporting Person<br>**4,519,361** | Aggregate Amount Beneficially Owned by Each Reporting Person<br>**4,519,361** | Aggregate Amount Beneficially Owned by Each Reporting Person<br>**4,519,361** | Aggregate Amount Beneficially Owned by Each Reporting Person<br>**4,519,361** |
| **12** | Check if the Aggregate Amount in Row (11) Excludes Certain Shares [ ] | Check if the Aggregate Amount in Row (11) Excludes Certain Shares [ ] | Check if the Aggregate Amount in Row (11) Excludes Certain Shares [ ] | Check if the Aggregate Amount in Row (11) Excludes Certain Shares [ ] |
| **13** | Percent of Class Represented by Amount in Row (11)<br>**11.1%** | Percent of Class Represented by Amount in Row (11)<br>**11.1%** | Percent of Class Represented by Amount in Row (11)<br>**11.1%** | Percent of Class Represented by Amount in Row (11)<br>**11.1%** |
| **14** | Type of Reporting Person<br>**PN** | Type of Reporting Person<br>**PN** | Type of Reporting Person<br>**PN** | Type of Reporting Person<br>**PN** |

---

------

---

| | | |
|:---|:---|:---|
| CUSIP No. 20451W101 | **13D** | Page 2 of 8 pages |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **1** | Names of Reporting Persons<br>**Samsara BioCapital GP, LLC** | Names of Reporting Persons<br>**Samsara BioCapital GP, LLC** | Names of Reporting Persons<br>**Samsara BioCapital GP, LLC** | Names of Reporting Persons<br>**Samsara BioCapital GP, LLC** |
| **2** | Check the Appropriate Box if a Member of a Group | Check the Appropriate Box if a Member of a Group | Check the Appropriate Box if a Member of a Group | (a) [ ](b) [ ] |
| **3** | SEC Use Only | SEC Use Only | SEC Use Only | SEC Use Only |
| **4** | Source of Funds (See Instructions)<br>**OO** | Source of Funds (See Instructions)<br>**OO** | Source of Funds (See Instructions)<br>**OO** | Source of Funds (See Instructions)<br>**OO** |
| **5** | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ] |
| **6** | Citizenship or Place of Organization<br>**Delaware** | Citizenship or Place of Organization<br>**Delaware** | Citizenship or Place of Organization<br>**Delaware** | Citizenship or Place of Organization<br>**Delaware** |
| **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **7** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>**0** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>**0** |
| **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **8** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power<br>**4,519,361** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power<br>**4,519,361** |
| **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **9** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power<br>**0** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power<br>**0** |
| **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **10** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power<br>**4,519,361** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power<br>**4,519,361** |
| **11** | Aggregate Amount Beneficially Owned by Each Reporting Person<br>**4,519,361** | Aggregate Amount Beneficially Owned by Each Reporting Person<br>**4,519,361** | Aggregate Amount Beneficially Owned by Each Reporting Person<br>**4,519,361** | Aggregate Amount Beneficially Owned by Each Reporting Person<br>**4,519,361** |
| **12** | Check if the Aggregate Amount in Row (11) Excludes Certain Shares [ ] | Check if the Aggregate Amount in Row (11) Excludes Certain Shares [ ] | Check if the Aggregate Amount in Row (11) Excludes Certain Shares [ ] | Check if the Aggregate Amount in Row (11) Excludes Certain Shares [ ] |
| **13** | Percent of Class Represented by Amount in Row (11)<br>**11.1%** | Percent of Class Represented by Amount in Row (11)<br>**11.1%** | Percent of Class Represented by Amount in Row (11)<br>**11.1%** | Percent of Class Represented by Amount in Row (11)<br>**11.1%** |
| **14** | Type of Reporting Person<br>**OO (Limited Liability Company)** | Type of Reporting Person<br>**OO (Limited Liability Company)** | Type of Reporting Person<br>**OO (Limited Liability Company)** | Type of Reporting Person<br>**OO (Limited Liability Company)** |

---

------

---

| | | |
|:---|:---|:---|
| CUSIP No. 20451W101 | **13D** | Page 3 of 8 pages |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **1** | Names of Reporting Persons<br>**Srinivas Akkaraju** | Names of Reporting Persons<br>**Srinivas Akkaraju** | Names of Reporting Persons<br>**Srinivas Akkaraju** | Names of Reporting Persons<br>**Srinivas Akkaraju** |
| **2** | Check the Appropriate Box if a Member of a Group | Check the Appropriate Box if a Member of a Group | Check the Appropriate Box if a Member of a Group | (a) [ ](b) [ ] |
| **3** | SEC Use Only | SEC Use Only | SEC Use Only | SEC Use Only |
| **4** | Source of Funds (See Instructions)<br>**OO** | Source of Funds (See Instructions)<br>**OO** | Source of Funds (See Instructions)<br>**OO** | Source of Funds (See Instructions)<br>**OO** |
| **5** | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) [ ] |
| **6** | Citizenship or Place of Organization<br>**USA** | Citizenship or Place of Organization<br>**USA** | Citizenship or Place of Organization<br>**USA** | Citizenship or Place of Organization<br>**USA** |
| **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **7** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>**2,444** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>**2,444** |
| **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **8** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power<br>**4,519,361** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power<br>**4,519,361** |
| **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **9** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power<br>**2,444** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power<br>**2,444** |
| **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **NUMBER OF<br>SHARES<br>BENEFICIALLY<br>OWNED BY EACH<br>REPORTING<br>PERSON<br>WITH** | **10** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power<br>**4,519,361** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power<br>**4,519,361** |
| **11** | Aggregate Amount Beneficially Owned by Each Reporting Person<br>**4,521,805** | Aggregate Amount Beneficially Owned by Each Reporting Person<br>**4,521,805** | Aggregate Amount Beneficially Owned by Each Reporting Person<br>**4,521,805** | Aggregate Amount Beneficially Owned by Each Reporting Person<br>**4,521,805** |
| **12** | Check if the Aggregate Amount in Row (11) Excludes Certain Shares [= ] | Check if the Aggregate Amount in Row (11) Excludes Certain Shares [= ] | Check if the Aggregate Amount in Row (11) Excludes Certain Shares [= ] | Check if the Aggregate Amount in Row (11) Excludes Certain Shares [= ] |
| **13** | Percent of Class Represented by Amount in Row (11)<br>**11.1%** | Percent of Class Represented by Amount in Row (11)<br>**11.1%** | Percent of Class Represented by Amount in Row (11)<br>**11.1%** | Percent of Class Represented by Amount in Row (11)<br>**11.1%** |
| **14** | Type of Reporting Person<br>**IN** | Type of Reporting Person<br>**IN** | Type of Reporting Person<br>**IN** | Type of Reporting Person<br>**IN** |

---

------

---

| | | |
|:---|:---|:---|
| CUSIP No. 20451W101 | **13D** | Page 4 of 8 pages |

---

**Item 1.&nbsp;&nbsp;&nbsp;&nbsp;Security and Issuer.**

This statement on Schedule 13D (the "Schedule 13D") relates to the Common Stock, par value $0.0001 per share ("Common Stock"), of Mineralys Therapeutics, Inc., a Delaware corporation (the "Issuer"), whose principal executive offices are located at 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania 19087.

**Item 2.&nbsp;&nbsp;&nbsp;&nbsp;Identity and Background.**

The Schedule 13D is being filed by the following persons (each a "Reporting Person" and, collectively, the "Reporting Persons"):

Samsara BioCapital, L.P. ("Samsara LP");

Samsara BioCapital GP, LLC ("Samsara LLC"); and

Srinivas Akkaraju, M.D., Ph.D.

Samsara LP and Samsara LLC are organized under the laws of the State of Delaware. Dr. Akkaraju is a citizen of the United States of America. The Reporting Persons are principally engaged in the business of investing in securities, including of the Issuer. The address of the Reporting Persons is 628 Middlefield Road, Palo Alto, CA 94301.

During the last five years, none of the Reporting Persons (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) were a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

**Item 3.**&nbsp;&nbsp;&nbsp;&nbsp;**Source and Amount of Funds or Other Consideration.**

Prior to the Issuer's initial public offering (the "IPO"), Samsara LP acquired preferred shares of the Issuer in a series of financing transactions for aggregate consideration of approximately $24.5 million. In connection with the completion of the IPO, on February 14, 2023, the preferred shares held by Samsara LP automatically converted into 3,581,861 shares of Common Stock.

Also on February 14, 2023, Samsara LP purchased 937,500 shares of Common Stock in the IPO at a price of $16.00 per share. Samsara LP obtained the funds for these acquisitions through capital contributions from its partners.

In addition, on February 9, 2023, the Issuer granted Dr. Akkaraju an option to purchase 44,000 shares of Common Stock at $16.00 per share in consideration for his continued service as a non-employee director of the Issuer. The option vests in 36 monthly installments beginning on March 9, 2023.

------

---

| | | |
|:---|:---|:---|
| CUSIP No. 20451W101 | **13D** | Page 5 of 8 pages |

---

**Item 4.&nbsp;&nbsp;&nbsp;&nbsp;Purpose of Transaction.**

*Registration Rights* 

Prior to the IPO, the Issuer granted Samsara LP, as well as other holders of the Issuer's convertible preferred stock and certain holders of its common stock, certain registration rights pursuant to the Amended and Restated Investors' Rights Agreement, dated June 1, 2022, as amended, by and among the Issuer and the stockholders party thereto (the "Investor Rights Agreement. Specifically the Issuer has granted Samsara LP demand, short-form and piggyback registration rights, which will terminate upon the earlier of (i) five years after the closing of the IPO or (ii) with respect to a particular holder, such time as Rule 144 or another similar exemption under the Securities Act of 1933, as amended, is available for the sale of all shares by such holder without limitation during a three-month period without registration.

The foregoing description of the Investor Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement filed as an exhibit to this Schedule 13D, and incorporated herein by reference.

*Lock-Up Agreement*

In connection with the IPO, the Reporting Persons entered into a letter agreement (the "Lock-Up Agreement"), with the several underwriters for the IPO (the "Underwriters"). Pursuant to the Lock-Up Agreement, the Reporting Persons agreed, without the prior written consent of the Underwriters and subject to limited exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities for a period of 180 days after the date of the final prospectus used in the IPO (the "Lock-Up Period").

The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, the form of which is filed as an exhibit to this Schedule 13D and is incorporated herein by reference.

*General*

The Reporting Persons acquired the securities described in this Schedule 13D for investment purposes and intend to review their investments in the Issuer on a continuing basis. Any actions the Reporting Persons might undertake may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Persons' review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market,

------

---

| | | |
|:---|:---|:---|
| CUSIP No. 20451W101 | **13D** | Page 6 of 8 pages |

---

industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments.

The Reporting Persons may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. In addition, the Reporting Persons may engage in discussions with management, the Issuer's board of directors (the "Board"), and securityholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary corporate transactions, such as: a merger, reorganization or other transaction that could result in the de-listing or de-registration of the Common Stock; sales or acquisitions of assets or businesses; changes to the capitalization or distribution policy of the Issuer; or other material changes to the Issuer's business or corporate structure, including changes in management or the composition of the Board. There can be no assurance, however, that the Reporting Persons will propose such a transaction, that any proposed transaction would receive the requisite approvals from the respective governing bodies and unitholders, as applicable, or that any such transaction would be successfully implemented.

Other than as described above, the Reporting Persons do not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)–(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Persons may change their purpose or formulate different plans or proposals with respect thereto at any time.

**Item 5.&nbsp;&nbsp;&nbsp;&nbsp;Interest in Securities of the Issuer.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) – (b)

The ownership information presented below represents beneficial ownership of Class A Common Stock of the Issuer as of the date hereof, based upon 40,856,653 shares of Common Stock outstanding as of February 14, 2023.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Reporting Person** | **Amount**<br>**beneficially**<br>**owned** | **Percent**<br>**of class:** | **Sole power to vote or to direct the vote:** | **Shared power to vote or to direct the vote:** | **Sole power to dispose or to direct the disposition**<br>**of:** | **Shared**<br>**power to**<br>**dispose or**<br>**to direct**<br>**the**<br>**disposition**<br>**of:** |
| Samsara BioCapital, L.P. | 4519361 | 11.1% | 0 | 4519361 | 0 | 4519361 |
| Samsara BioCapital GP, LLC | 4519361 | 11.1% | 0 | 4519361 | 0 | 4519361 |
| Srinivas Akkaraju | 4521805 | 11.1% | 2444 | 4519361 | 2444 | 4519361 |

---

Samsara LP is the record holder of 4,519,361 shares of Common Stock. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP.

------

---

| | | |
|:---|:---|:---|
| CUSIP No. 20451W101 | **13D** | Page 7 of 8 pages |

---

In addition, Dr. Akkaraju holds an option to purchase shares of Common Stock that will be exercisable with respect to 2,444 shares of Common Stock within 60 days of the date hereof.

(c)Except as described in Items 3 and 4, during the past 60 days, the Reporting Persons have not effected any transactions in the Common Stock.

(d)None.

(e)Not applicable.

**Item 6.&nbsp;&nbsp;&nbsp;&nbsp;Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.**

Item 4 above summarizes certain provisions of the Investor Rights Agreement and Lock-Up Agreement and is incorporated herein by reference. A copy of each such agreement is attached as an exhibit to this Schedule 13D, and is incorporated herein by reference.

Except as set forth herein, neither the Reporting Persons nor any Related Person has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

**Item 7.&nbsp;&nbsp;&nbsp;&nbsp;Materials to be Filed as Exhibits** 

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 1 | <u>[Joint Filing Agreement.](exhibit1-schedule13d.htm)</u> |
| 2 | <u>[Amended and Restated Investors' Rights Agreement, dated June 1, 2022, as amended, by and among the Issuer and certain of its stockholders (incorporated by reference to Exhibit 4.2 to the Issuer's Registration Statement on Form S-1 (File No. 333-269282)).](https://www.sec.gov/Archives/edgar/data/1933414/000162828023001171/exhibit42-sx1.htm)</u> |
| 3 | <u>[Form of Lock-Up Agreement (incorporated by reference to the Form of Underwriting Agreement filed as Exhibit 1.1 the Issuer's Registration Statement on Form S-1 (File No. 333-269282)).](https://www.sec.gov/Archives/edgar/data/1933414/000162828023001963/exhibit11-sx1a1.htm)</u> |

---

------

---

| | | |
|:---|:---|:---|
| CUSIP No. 20451W101 | **13D** | Page 8 of 8 pages |

---

**SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | | |
|:---|:---|:---|
| **Date:** February 24, 2023 | | |
| | **SAMSARA BIOCAPITAL, L.P.** | **SAMSARA BIOCAPITAL, L.P.** |
|  | By: | /s/ Abrar Hussain |
|  | Name: | Abrar Hussain |
|  | Title: | Attorney-in-Fact |
|  | **SAMSARA BIOCAPITAL GP, LLC** | **SAMSARA BIOCAPITAL GP, LLC** |
|  | By: | /s/ Abrar Hussain |
|  | Name: | Abrar Hussain |
|  | Title: | Attorney-in-Fact |
|  | **SRINIVAS AKKARAJU, M.D., PH.D.** | **SRINIVAS AKKARAJU, M.D., PH.D.** |
|  | By: | /s/ Abrar Hussain |
|  | Name: | Abrar Hussain |
|  | Title: | Attorney-in-Fact |

---

## Exhibit 99.1

**Exhibit 1**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 24th day of February, 2023.

---

| | | |
|:---|:---|:---|
| **SAMSARA BIOCAPITAL, L.P.** | **SAMSARA BIOCAPITAL, L.P.** | **SAMSARA BIOCAPITAL, L.P.** |
| By: | /s/ Abrar Hussain | /s/ Abrar Hussain |
| Name: | Name: | Abrar Hussain |
| Title: | Title: | Attorney-in-Fact |
| **SAMSARA BIOCAPITAL GP, LLC** | **SAMSARA BIOCAPITAL GP, LLC** | **SAMSARA BIOCAPITAL GP, LLC** |
| By: | /s/ Abrar Hussain | /s/ Abrar Hussain |
| Name: | Name: | Abrar Hussain |
| Title: | Title: | Attorney-in-Fact |
| **SRINIVAS AKKARAJU, M.D., PH.D.** | **SRINIVAS AKKARAJU, M.D., PH.D.** | **SRINIVAS AKKARAJU, M.D., PH.D.** |
| By: | /s/ Abrar Hussain | /s/ Abrar Hussain |
| Name: | Name: | Abrar Hussain |
| Title: | Title: | Attorney-in-Fact |

---

<br>